Atlas Trials

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC

Clinical trial NCT06599827 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06599827
Sponsor
Shanghai Zhongshan Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rectal Cancer
Start date
2024-09-20
Primary completion
2026-09-20
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.